PROJECT

Projects

Summary of Investment Information

Project Number

45935

Company Name

THE BIOLOGICALS AND VACCINES INSTITUTE OF SOUTHERN AFRICA (PTY) LTD

Date SPI Disclosed

Dec 8, 2025

Country

South Africa

Region

Africa

Projected Board Date

Jan 29, 2026

Environmental Category

B - Limited

Status

Pending Disbursement

Last Updated Date

Mar 25, 2026

Department

CM3S2 - Regional Industry - MAS Africa/MAS Svcs - Est & Sth Africa

Industry

other

Previous Events

Approved : Feb 27, 2026
Signed : Mar 16, 2026

Sector

Pharmaceuticals and Medicine Manufacturing

Project Description

The proposed investment seeks to support, the Biologicals and Vaccines Institute of Southern Africa ('Biovac' or the 'Company'), a South African biopharmaceutical company based in Cape Town, to expand its suite of products which includes partnering with international vaccine entities through technology transfer agreements for fill and finish manufacturing of vaccines on the continent as well as an end to end scale up of an internally developed Oral Cholera Vaccine (OCV). The project will entail developing a new state-of -the-art “green” facility for end-to-end manufacturing to manufacture up to 250 million doses of vaccines per year, thus helping reduce Africa’s over dependence on imported vaccines. It will be comprised of (i) one glass vial fill & finish suite, (ii) one drug substance suite, for the manufacturing of inactivated OCV, and (iii) one blow-fill-seal (plastic line) for Fill & Finish of OCV and other vaccines (the Project).

Associated Advisory Engagement

 n.a.

Sponsor / Cost / Location

Development Impact

E&S Category Rationale / Risks and Mitigation